Discover how ONCrg can support your drug development program in Ovarian Cancer.

As we continue to expand development of the ONCrg family of resources in additional tumor areas, we value client input regarding priority. To learn more about the status of our Ovarian Cancer resources, please contact Mike Reynolds or call 650-485-2626